Pacific Biosciences of California Past Earnings Performance
Past criteria checks 0/6
Pacific Biosciences of California's earnings have been declining at an average annual rate of -40.2%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 18.7% per year.
Key information
-40.2%
Earnings growth rate
-30.8%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | 18.7% |
Return on equity | -87.0% |
Net Margin | -227.7% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Pacific Biosciences' Cost Cuts Won't Offset Rising Competition
Nov 12Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company
Nov 07Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?
Oct 16Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely
Sep 20Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing
Aug 21Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper
Jul 02We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt
Jun 08Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas
Jun 03These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat
Apr 25It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks
Apr 16Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership
Mar 19Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth
Feb 08With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For
Feb 01What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S
Dec 18Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?
Nov 13The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%
Aug 28Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?
Jul 31Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?
Jul 06Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt
May 25Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?
Mar 29Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?
Feb 26Revenue & Expenses Breakdown
How Pacific Biosciences of California makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 173 | -394 | 165 | 146 |
30 Jun 24 | 189 | -400 | 172 | 168 |
31 Mar 24 | 200 | -297 | 174 | 182 |
31 Dec 23 | 201 | -307 | 170 | 187 |
30 Sep 23 | 170 | -309 | 169 | 185 |
30 Jun 23 | 146 | -319 | 162 | 185 |
31 Mar 23 | 134 | -321 | 161 | 189 |
31 Dec 22 | 128 | -314 | 161 | 193 |
30 Sep 22 | 137 | -299 | 153 | 193 |
30 Jun 22 | 140 | -206 | 148 | 173 |
31 Mar 22 | 135 | -175 | 138 | 145 |
31 Dec 21 | 131 | -181 | 124 | 113 |
30 Sep 21 | 122 | -37 | 105 | 88 |
30 Jun 21 | 106 | -77 | 94 | 77 |
31 Mar 21 | 92 | -59 | 80 | 69 |
31 Dec 20 | 79 | 29 | 73 | 64 |
30 Sep 20 | 80 | -46 | 84 | 61 |
30 Jun 20 | 83 | -51 | 71 | 59 |
31 Mar 20 | 90 | -53 | 75 | 59 |
31 Dec 19 | 91 | -84 | 75 | 60 |
30 Sep 19 | 82 | -115 | 62 | 62 |
30 Jun 19 | 79 | -111 | 68 | 61 |
31 Mar 19 | 76 | -109 | 64 | 62 |
31 Dec 18 | 79 | -103 | 63 | 63 |
30 Sep 18 | 84 | -93 | 58 | 62 |
30 Jun 18 | 89 | -90 | 58 | 63 |
31 Mar 18 | 88 | -93 | 59 | 65 |
31 Dec 17 | 93 | -92 | 59 | 65 |
30 Sep 17 | 94 | -90 | 58 | 66 |
30 Jun 17 | 96 | -86 | 56 | 68 |
31 Mar 17 | 97 | -79 | 51 | 68 |
31 Dec 16 | 91 | -74 | 48 | 68 |
30 Sep 16 | 101 | -57 | 48 | 66 |
30 Jun 16 | 90 | -37 | 46 | 65 |
31 Mar 16 | 94 | -31 | 46 | 62 |
31 Dec 15 | 93 | -32 | 45 | 60 |
30 Sep 15 | 73 | -49 | 42 | 58 |
30 Jun 15 | 80 | -60 | 41 | 54 |
31 Mar 15 | 67 | -67 | 40 | 51 |
31 Dec 14 | 61 | -66 | 38 | 48 |
30 Sep 14 | 53 | -64 | 37 | 47 |
30 Jun 14 | 40 | -76 | 38 | 46 |
31 Mar 14 | 34 | -77 | 38 | 45 |
31 Dec 13 | 28 | -79 | 39 | 45 |
Quality Earnings: PACB is currently unprofitable.
Growing Profit Margin: PACB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PACB is unprofitable, and losses have increased over the past 5 years at a rate of 40.2% per year.
Accelerating Growth: Unable to compare PACB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PACB is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).
Return on Equity
High ROE: PACB has a negative Return on Equity (-87.01%), as it is currently unprofitable.